Connor Clark & Lunn Investment Management Ltd. Has $28.25 Million Stock Holdings in Charles River Laboratories International, Inc. $CRL

Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 180,564 shares of the medical research company’s stock after selling 10,704 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.37% of Charles River Laboratories International worth $28,251,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CRL. BNP Paribas Financial Markets raised its holdings in Charles River Laboratories International by 22.6% in the third quarter. BNP Paribas Financial Markets now owns 109,879 shares of the medical research company’s stock worth $17,192,000 after purchasing an additional 20,224 shares during the period. Magnetar Financial LLC increased its position in shares of Charles River Laboratories International by 1,379.8% in the 3rd quarter. Magnetar Financial LLC now owns 23,173 shares of the medical research company’s stock valued at $3,626,000 after buying an additional 21,607 shares in the last quarter. Legal & General Group Plc increased its position in shares of Charles River Laboratories International by 1.9% in the 3rd quarter. Legal & General Group Plc now owns 108,245 shares of the medical research company’s stock valued at $16,934,000 after buying an additional 2,044 shares in the last quarter. Vestcor Inc raised its stake in Charles River Laboratories International by 37.0% during the 3rd quarter. Vestcor Inc now owns 4,968 shares of the medical research company’s stock worth $777,000 after buying an additional 1,342 shares during the period. Finally, Swiss National Bank lifted its holdings in Charles River Laboratories International by 1.5% during the third quarter. Swiss National Bank now owns 95,200 shares of the medical research company’s stock worth $14,895,000 after acquiring an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $152.22 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The firm has a market cap of $7.49 billion, a price-to-earnings ratio of -51.43, a price-to-earnings-growth ratio of 2.89 and a beta of 1.64. The stock’s 50-day moving average is $192.53 and its 200-day moving average is $180.94. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same period last year, the company earned $2.66 earnings per share. Charles River Laboratories International’s quarterly revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Argus set a $200.00 price objective on Charles River Laboratories International in a research report on Monday, November 17th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research note on Monday, December 1st. Finally, Barclays dropped their target price on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, February 19th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $203.57.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.